Seres Therapeutics Stock In The News
| MCRB Stock | USD 0.92 0.04 4.55% |
Our overall analysis of Seres Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Seres Therapeutics. The specific impact of Seres Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Seres Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Seres Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Seres Therapeutics Backtesting and Seres Therapeutics Hype Analysis. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.
Seres |
Seres Therapeutics Today Top News and Investor Outlook
Seres Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Seres and other traded companies coverage with news coverage. We help investors stay connected with Seres headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Seres Stock performance. Please note that trading solely based on the Seres Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Seres Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Seres earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Seres Therapeutics that are available to investors today. That information is available publicly through Seres media outlets and privately through word of mouth or via Seres internal channels. However, regardless of the origin, that massive amount of Seres data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Seres Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Seres Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Seres Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Seres Therapeutics alpha.
Seres Largest EPS Surprises
Earnings surprises can significantly impact Seres Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-03-02 | 2019-12-31 | -0.28 | -0.25 | 0.03 | 10 | ||
2024-08-13 | 2024-06-30 | -0.27 | -0.22 | 0.05 | 18 | ||
2021-03-02 | 2020-12-31 | -0.28 | -0.23 | 0.05 | 17 | ||
2015-11-10 | 2015-09-30 | -0.32 | -0.38 | -0.06 | 18 | ||
2024-05-08 | 2024-03-31 | -0.34 | -0.27 | 0.07 | 20 | ||
2023-03-07 | 2022-12-31 | -0.46 | -0.54 | -0.08 | 17 |
Seres Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Seres Therapeutics Stock. Current markets are slightly bearish. About 58% of major world exchanges and indexes are down. See today's market update for more information.
22nd of November 2024
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference at gurufocus.com
19th of November 2024
Seres Therapeutics chief legal officer sells shares worth 474 at investing.com
15th of November 2024
Little Excitement Around Seres Therapeutics, Inc.s Revenues As Shares Take 30 percent Poun... at simplywall.st
14th of November 2024
Earnings call Seres Therapeutics reports key Q3 2024 milestones at investing.com
13th of November 2024
Seres Therapeutics GAAP EPS of -0.33 misses by 0.25 at seekingalpha.com
6th of November 2024
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates o... at finance.yahoo.com
29th of October 2024
Seres Therapeutics executive sells stock for 2,749 at investing.com
24th of October 2024
This Verizon Analyst Is No Longer Bullish Here Are Top 5 Downgrades For Thursday at benzinga.com
26th of September 2024
Seres Therapeutics Stockholders Approve Sale of VOWST to Nestl Health Science Sale Expecte... at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seres Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seres Therapeutics' short interest history, or implied volatility extrapolated from Seres Therapeutics options trading.
Check out Seres Therapeutics Backtesting and Seres Therapeutics Hype Analysis. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.